ENLV

EnlivexB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.10

+29.4% vs current

Most likely

Base case

50%

Probability

Target price

$0.80

-5.9% vs current

B-

Bear case

25%

Probability

Target price

$0.40

-52.9% vs current

AI sentiment snapshot

Latest data as of 2026-05-28

AI commentary

News tone is mixed but slightly constructive on execution because the company has a real Phase 2b enrollment milestone, a treasury narrative, and a financing/capital-allocation hook, while the Nasdaq minimum-bid notice keeps a material overhang in place. The latest observable price in the packet is $0.782 on 2026-05-27, so the shares were still below the $1.00 threshold after the recent company news flow; I could not isolate a clean earnings-day reaction because the May 27 treasury update is a confounder. No analyst revisions or fresh estimate changes were available in the checked sources, so this remains a thin-coverage monitoring setup rather than a high-conviction rerate.

RankAlpha Sentiment Codex - 2026-05-28

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-03-24catalystDebt financing and repurchase authorization frame capital-allocation riskHigh impact

The March 24 company release outlined $21M of debt financing, RAIN token-related updates, and a $20M share repurchase program. This gives ENLV more treasury optionality, but it also makes long-horizon sentiment dependent on capital-allocation discipline, cash runway, and the durability of token-linked asset values. [#PR-2026-03-24]

2026-03-25eventFY2025 results were driven by treasury marksMedium impact

The company's March 25 Form 6-K confirms it issued year-end 2025 results showing $1.23B net income and $25.48 EPS, but the release says those figures were driven by appreciation in treasury and treasury-related derivative assets rather than operating revenue. That supports the treasury narrative, but it does not de-risk the clinical business. [#6-K-2026-03-25]

2026-05-27eventRain treasury update strengthened the non-clinical storyMedium impact

On May 27, Enlivex said Rain's added liquidity lifted the protocol to top-tier prediction-market positioning and disclosed roughly 79.6B RAIN tokens valued at about $919M plus a large call option on additional tokens. That reinforces the treasury thesis, but also leaves ENLV exposed to token-price volatility and mark-to-market swings. [#PR-2026-05-27]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-28 • Updated nightlySource: Internal modelMethodology